MaxQ AI’s ICH and stroke software to be available on Philips CT systems

MaxQ AI has announced that its AI-based intracranial hemorrhage (ICH) and stroke software will soon be integrated into Philips CT scanners. The first round of deployments is expected in 2020.

MaxQ AI’s Accipio ICH and stroke platform uses deep learning to evaluate medical images and automatically identify those that show signs of ICH. The platform will be available for the newest line of Philips CT systems and can be installed as an upgrade to existing equipment.

“Through this powerful collaboration, we will empower physicians to better identify and prioritize patients with a suspected ICH, which have the potential to save lives, improve the quality of care, and lower healthcare costs,” Gene Saragnese, CEO of MaxQ AI, said in a prepared statement.

“We are advancing patient care by co-creating with our customers to bring innovations in CT system design, workflow, radiation dose management, image quality, advanced clinical applications and improved total cost of ownership,” Karim Boussebaa, general manager of computed tomography and advanced molecular imaging at Philips, said in the same statement. “As healthcare continues to transform from a volume- to a value-based approach, and the amount of data available for each clinical decision dramatically grows, the integration of MaxQ's Accipio AI-powered solutions with our CT systems supports our ambition to achieve the quadruple aim: improved outcomes, enhanced patient experience, increased staff satisfaction, and lowered cost of care delivery.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.